Key result
COMPASS analysis details predictors and incidence of major gastrointestinal bleeding with rivaroxaban and aspirin regimens.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to GI bleeding predictors with these regimens; extends COMPASS safety insights for risk stratification.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question. Aspirin, low-dose rivaroxaban, and their combination were discussed regarding the incidence and predictors of major gastrointestinal bleeding in a letter concerning the COMPASS trial.
Synapse has enriched 10 related papers. Consider them for comparative context: